Small intestine carcinoma
diseaseOn this page
Also known as cancer of small bowelcancer of the small bowelcarcinoma of small bowelcarcinoma of small intestinecarcinoma of the small bowelcarcinoma of the small intestinesmall bowel cancersmall bowel carcinomasmall intestinal cancersmall intestinal carcinomasmall intestine cancersmall intestine cancer, NOS
Summary
Small intestine carcinoma (MONDO:0005522) is a cancer with 1 GWAS associations across 2 studies and 113 clinical trials. Top therapeutic interventions include dextromethorphan, imatinib, and ondansetron. A subtype of small intestine cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- GWAS associations: 1
- Clinical trials: 113
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | small intestine carcinoma |
| Mondo ID | MONDO:0005522 |
| EFO | EFO:0005588 |
| DOID | DOID:4907 |
| ICD-11 | 1484520499 |
| NCIT | C7724 |
| SNOMED CT | 448664009 |
| UMLS | C0238196 |
| MedGen | 65952 |
| GARD | 0024201 |
| Anatomy (UBERON) | UBERON:0002108 |
| Is cancer (heuristic) | yes |
Also known as: cancer of small bowel · cancer of the small bowel · carcinoma of small bowel · carcinoma of small intestine · carcinoma of the small bowel · carcinoma of the small intestine · small bowel cancer · small bowel carcinoma · small intestinal cancer · small intestinal carcinoma · small intestine cancer · small intestine cancer, NOS · small intestine carcinoma
Data availability: 1 GWAS association (2 studies) · 1 cell line · 11 intOGen driver records.
Disease family
This is a subtype of small intestine cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › intestinal neoplasm › small intestine neoplasm › small intestine cancer › small intestine carcinoma
Related subtypes (5): duodenum cancer, ileum cancer, small intestine lymphoma, small intestinal sarcoma, jejunal cancer
Subtypes (3): small intestine adenocarcinoma, squamous cell carcinoma of the small intestine, carcinoma of duodenum
Genetics & variants
GWAS landscape
1 GWAS associations across 2 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs9267989 | 4e-08 | NOTCH4 - TSBP1-AS1 | ? | 1.52 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90432150 | Jiang Y | 2023 | 116,382 | 213,325 | A cross-disorder study to identify causal relationships, shared genetic variants, and genes across 21 digestive disorders. |
| GCST90041893 | Jiang L | 2021 | 208 | 456,068 | A generalized linear mixed model association tool for biobank-scale data. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs9267989 | 6 | 32251543 | G>A,T | 0.05 | intergenic_variant | NOTCH4 - TSBP1-AS1 | 4e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 113.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 42 |
| Not specified | 33 |
| PHASE2 | 26 |
| PHASE1/PHASE2 | 6 |
| PHASE3 | 5 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00003600 | PHASE3 | COMPLETED | Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy |
| NCT00003687 | PHASE3 | COMPLETED | Treatment for Chronic Pain in Patients With Advanced Cancer |
| NCT00005590 | PHASE3 | COMPLETED | Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma |
| NCT00006348 | PHASE3 | COMPLETED | Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment |
| NCT00026468 | PHASE2/PHASE3 | WITHDRAWN | Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis |
| NCT00445497 | PHASE3 | UNKNOWN | Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia |
| NCT02949219 | PHASE2 | ACTIVE_NOT_RECRUITING | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery |
| NCT05194995 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation |
| NCT05565417 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas |
| NCT00003522 | PHASE2 | TERMINATED | Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine |
| NCT00003939 | PHASE2 | COMPLETED | Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma |
| NCT00004066 | PHASE2 | COMPLETED | Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma |
| NCT00004895 | PHASE2 | COMPLETED | Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery |
| NCT00004910 | PHASE1/PHASE2 | COMPLETED | Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction |
| NCT00004911 | PHASE1/PHASE2 | COMPLETED | Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction |
| NCT00005049 | PHASE2 | COMPLETED | Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer |
| NCT00005804 | PHASE2 | COMPLETED | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer |
| NCT00005874 | PHASE2 | COMPLETED | Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas |
| NCT00006039 | PHASE2 | COMPLETED | Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin’s Lymphoma |
| NCT00006357 | PHASE1/PHASE2 | COMPLETED | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma |
| NCT00006379 | PHASE2 | COMPLETED | Non-Ablative Allo HSCT For Hematologic Malignancies or SAA |
| NCT00012246 | PHASE2 | TERMINATED | Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract |
| NCT00019474 | PHASE2 | COMPLETED | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer |
| NCT00025441 | PHASE2 | COMPLETED | Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors |
| NCT00079261 | PHASE2 | COMPLETED | Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin’s Lymphoma |
| NCT00410462 | PHASE2 | UNKNOWN | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma |
| NCT00416351 | PHASE1/PHASE2 | COMPLETED | Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin’s Lymphoma That Has Relapsed or Not Responded to Previous Treatment |
| NCT00433550 | PHASE2 | COMPLETED | Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer |
| NCT00445965 | PHASE2 | COMPLETED | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer |
| NCT00474994 | PHASE2 | COMPLETED | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas |
| NCT00589563 | PHASE2 | COMPLETED | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer |
| NCT00621036 | PHASE2 | WITHDRAWN | Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma |
| NCT00669812 | PHASE2 | UNKNOWN | High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma |
| NCT00903396 | PHASE2 | TERMINATED | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer |
| NCT02216149 | PHASE2 | TERMINATED | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow |
| NCT04491955 | PHASE2 | COMPLETED | Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers |
| NCT04505553 | PHASE2 | COMPLETED | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer |
| NCT06690281 | PHASE2 | WITHDRAWN | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies |
| NCT02381561 | PHASE1 | ACTIVE_NOT_RECRUITING | Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy |
| NCT05277766 | PHASE1 | RECRUITING | Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXTROMETHORPHAN | 4 | 3 |
| IMATINIB | 4 | 3 |
| ONDANSETRON | 4 | 3 |
| EPIRUBICIN HYDROCHLORIDE | 4 | 2 |
| IXABEPILONE | 4 | 2 |
| LEUCOVORIN CALCIUM | 4 | 2 |
| LEVOFLOXACIN ANHYDROUS | 4 | 2 |
| PHENYLBUTANOIC ACID | 4 | 2 |
| TACROLIMUS ANHYDROUS | 4 | 2 |
| CIPROFLOXACIN | 4 | 1 |
| CLADRIBINE | 4 | 1 |
| CLOFARABINE | 4 | 1 |
| DACTINOMYCIN | 4 | 1 |
| EPOETIN ALFA | 4 | 1 |
| FLOXURIDINE | 4 | 1 |
| FRUQUINTINIB | 4 | 1 |
| GANCICLOVIR | 4 | 1 |
| HYDROXYUREA | 4 | 1 |
| IMETELSTAT SODIUM | 4 | 1 |
| MORPHINE SULFATE | 4 | 1 |
| OCTREOTIDE ACETATE | 4 | 1 |
| OFLOXACIN | 4 | 1 |
| PALONOSETRON HYDROCHLORIDE | 4 | 1 |
| PHENOBARBITAL | 4 | 1 |
| SARGRAMOSTIM | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| THIOTEPA | 4 | 1 |
| TRABECTEDIN | 4 | 1 |
| VANDETANIB | 4 | 1 |
| ALVOCIDIB | 3 | 3 |
Related Atlas pages
- Drugs: Dextromethorphan, Imatinib, Ondansetron, Epirubicin, Ixabepilone, Levofloxacin, Phenylbutanoic Acid, Tacrolimus, Ciprofloxacin, Cladribine, Clofarabine, Dactinomycin, Epoetin Alfa, Floxuridine, Fruquintinib, Ganciclovir, Hydroxyurea, Imetelstat, Morphine, Octreotide Acetate, Ofloxacin, Palonosetron, Phenobarbital, Sargramostim, Sunitinib Malate, Thiotepa, Trabectedin, Vandetanib, Alvocidib